Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPIA | P62937 | 1/20 | 0.76 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.72 |
| ▸ | LMNA | P02545 | 2/20 | 0.72 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.72 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.72 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.72 |
| ▸ | EDNRA | P25101 | 1/20 | 0.72 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.72 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.72 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.72 |
| ▸ | PKM | P14618 | 6/20 | 0.68 |
| ▸ | MEN1 | O00255 | 6/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.66 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.65 |
| ▸ | POLB | P06746 | 2/20 | 0.62 |
| ▸ | ATM | Q13315 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16273104 | 0.86 | SCN3A (0.74) | PPIAALDH1A1LMNATDP1KDM4E | |
| SCHEMBL3066836 | 0.85 | LMNA (0.79) | PPIAALDH1A1LMNATDP1KDM4E | |
| SCHEMBL13212127 | 0.85 | PTPN1 (0.80) | PPIAALDH1A1LMNATDP1KDM4E | |
| SCHEMBL13452528 | 0.84 | MEN1 (0.71) | PPIAALDH1A1LMNATDP1KDM4E | |
| SCHEMBL13180843 | 0.84 | ALDH1A1 (0.72) | PPIAALDH1A1LMNATDP1KDM4E | |
| Sulfathiazole SCHEMBL30130508 | 0.84 | ALDH1A1 (1.00) | PPIAALDH1A1LMNATDP1KDM4E | |
| SCHEMBL184078 | 0.84 | ALDH1A1 (0.72) | PPIAALDH1A1LMNATDP1KDM4E | |
| SCHEMBL183995 | 0.84 | ALDH1A1 (0.72) | PPIAALDH1A1LMNATDP1KDM4E | |
| Sulfathiazole SCHEMBL94165 | 0.84 | ALDH1A1 (1.00) | PPIAALDH1A1LMNATDP1KDM4E | |
| SCHEMBL1650814 | 0.84 | ALDH1A1 (0.72) | PPIAALDH1A1LMNATDP1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10316026-B2 | Method for removing dimethoxybenzyl group | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2019-06-11 | — | — | US | disclosed |
| US-10316026-B2 | Method for removing dimethoxybenzyl group | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2019-06-11 | — | — | US | disclosed |
| EP-3372583-A1 | METHOD FOR REMOVING DIMETHOXYBENZYL GROUP | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2018-09-12 | — | — | EP | disclosed |
| US-20180251448-A1 | METHOD FOR REMOVING DIMETHOXYBENZYL GROUP | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2018-09-06 | — | — | US | disclosed |
| WO-2017078123-A1 | METHOD FOR REMOVING DIMETHOXYBENZYL GROUP | 第一三共株式会社 | 2017-05-11 | — | — | WO | disclosed |
| US-8124610-B2 | Sodium channel inhibitors | ICAGEN INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-7615563-B2 | Compositions useful as inhibitors of voltage-gated sodium channels | VERTEX PHARMACEUTICALS INCORPORATED | 2009-11-10 | — | — | US | disclosed |
| US-20090023740-A1 | SODIUM CHANNEL INHIBITORS | ICAGEN (US) | 2009-01-22 | — | — | US | disclosed |
| US-20080227785-A1 | 2,4,6-TRIAMINO-1,3,5-TRIAZINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2008-09-18 | — | — | US | disclosed |
| US-7375222-B2 | 2,4,6-Triamino-1,3,5-triazine derivative | ASTELLAS PHARMA INC. (JP) | 2008-05-20 | — | — | US | disclosed |
| US-7375222-B2 | 2,4,6-Triamino-1,3,5-triazine derivative | ASTELLAS PHARMA INC. (JP) | 2008-05-20 | — | — | US | disclosed |
| US-20060025415-A1 | Compositions useful as inhibitors of voltage-gated sodium channels | VERTEX PHARMACEUTICALS INCORPORATED | 2006-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180251448-A1 | METHOD FOR REMOVING DIMETHOXYBENZYL GROUP | DDT, ALKBH5, DDO | PPIA 4564/4885ALDH1A1 1602/4885LMNA 1411/4885 |
| US-20090023740-A1 | SODIUM CHANNEL INHIBITORS | TRPV1, SCN1A, SCN2A | PPIA 1667/4885ALDH1A1 3333/4885LMNA 2921/4885 |
| US-20060025415-A1 | Compositions useful as inhibitors of voltage-gated sodium channels | SCNN1G, KCNN3, KCNN2 | PPIA 2483/4885ALDH1A1 2811/4885LMNA 1374/4885 |
| US-20080227785-A1 | 2,4,6-TRIAMINO-1,3,5-TRIAZINE DERIVATIVE | KCNT1, KCNMA1, KCNJ2 | PPIA 4870/4885ALDH1A1 2383/4885LMNA 3239/4885 |
| US-10316026-B2 | Method for removing dimethoxybenzyl group | DDT, ALKBH5, DDO | PPIA 4564/4885ALDH1A1 1602/4885LMNA 1411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.